Jose Maria Castellano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8915956/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Polypill Strategy to Improve Adherence. Journal of the American College of Cardiology, 2014, 64, 2071-2082.	2.8	290
2	Global burden of CVD: focus on secondary prevention of cardiovascular disease. International Journal of Cardiology, 2015, 201, S1-S7.	1.7	219
3	Assessing the Impact of MedicationÂAdherence on Long-Term Cardiovascular Outcomes. Journal of the American College of Cardiology, 2016, 68, 789-801.	2.8	208
4	Prognostic implications of neutrophilâ€lymphocyte ratio in COVIDâ€19. European Journal of Clinical Investigation, 2021, 51, e13404.	3.4	92
5	Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet, The, 2021, 398, 1133-1146.	13.7	87
6	Defective sarcoplasmic reticulum–mitochondria calcium exchange in aged mouse myocardium. Cell Death and Disease, 2014, 5, e1573-e1573.	6.3	85
7	A Polypill Strategy to Improve Clobal Secondary Cardiovascular Prevention. Journal of the American College of Cardiology, 2014, 64, 613-621.	2.8	74
8	The Relationships Between Cardiovascular Disease and Diabetes. Endocrinology and Metabolism Clinics of North America, 2014, 43, 41-57.	3.2	74
9	Lipid profile, cardiovascular disease and mortality in a Mediterranean high-risk population: The ESCARVAL-RISK study. PLoS ONE, 2017, 12, e0186196.	2.5	72
10	Putting polypills into practice: challenges and lessons learned. Lancet, The, 2017, 389, 1066-1074.	13.7	68
11	Altered FoF1 ATP synthase and susceptibility to mitochondrial permeability transition pore during ischaemia and reperfusion in aging cardiomyocytes. Thrombosis and Haemostasis, 2015, 113, 441-451.	3.4	46
12	Association of Increased Plasma Cardiotrophin-1 With Inappropriate Left Ventricular Mass in Essential Hypertension. Hypertension, 2007, 50, 977-983.	2.7	44
13	Anticoagulation during pregnancy in patients with a prosthetic heart valve. Nature Reviews Cardiology, 2012, 9, 415-424.	13.7	40
14	Cardiac magnetic resonance evaluation of left ventricular remodelling distribution in cardiac amyloidosis. Heart, 2014, 100, 1688-1695.	2.9	39
15	[18 F]-FDG PET and Localized Fibrous Mesothelioma. Lung, 2003, 181, 49-54.	3.3	34
16	The links between complex coronary disease, cerebrovascular disease, and degenerative brain disease. Annals of the New York Academy of Sciences, 2012, 1254, 99-105.	3.8	34
17	The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention. International Journal of Cardiology, 2015, 201, S15-S23.	1.7	32
18	Utilidad de un policomprimido cardiovascular enÂelÂtratamiento deÂpacientes enÂprevención secundaria enÂEspaña: unÂestudio deÂcoste-efectividad. Revista Espanola De Cardiologia, 2017, 70, 42-49.	1.2	28

JOSE MARIA CASTELLANO

#	Article	IF	CITATIONS
19	The cardiovascular polypill: clinical data and ongoing studies. International Journal of Cardiology, 2015, 201, S8-S14.	1.7	27
20	Risk Score for Predicting In-Hospital Mortality in COVID-19 (RIM Score). Diagnostics, 2021, 11, 596.	2.6	27
21	Obesity, Metabolic Syndrome, and Diabetes: Cardiovascular Implications and Therapy. Revista Espanola De Cardiologia (English Ed), 2008, 61, 752-764.	0.6	26
22	Aiming at Strategies for a Complex Problem of Medical Nonadherence. Global Heart, 2013, 8, 263.	2.3	26
23	Hemogram as Marker of In-Hospital Mortality in Covid-19. Journal of Investigative Medicine, 2021, 69, 962-969.	1.6	26
24	Marfan Syndrome. Seminars in Cardiothoracic and Vascular Anesthesia, 2014, 18, 260-271.	1.0	25
25	Dual-Source CT Coronary Angiogram in Heart Transplant Recipients in Comparison With Dobutamine Stress Echocardiography for Detection of Cardiac Allograft Vasculopathy. Transplantation, 2009, 87, 587-590.	1.0	24
26	Clinical Effectiveness of the Cardiovascular Polypill in a Real-Life Setting in Patients with Cardiovascular Risk: The SORS Study. Archives of Medical Research, 2019, 50, 31-40.	3.3	24
27	A 30-month worksite-based lifestyle program to promote cardiovascular health in middle-aged bank employees: Design of the TANSNIP-PESA randomized controlled trial. American Heart Journal, 2017, 184, 121-132.	2.7	22
28	Evolution of the Polypill Concept and Ongoing Clinical Trials. Canadian Journal of Cardiology, 2014, 30, 520-526.	1.7	21
29	Mechanisms of Stroke in Atrial Fibrillation. Cardiac Electrophysiology Clinics, 2014, 6, 5-15.	1.7	21
30	Promoting Cardiovascular Health Worldwide: Strategies, Challenges, and Opportunities. Revista Espanola De Cardiologia (English Ed), 2014, 67, 724-730.	0.6	21
31	Estimation of the major cardiovascular events prevention with Inclisiran. Atherosclerosis, 2020, 313, 76-80.	0.8	19
32	Atrial fibrillation, stroke, and quality of life. Annals of the New York Academy of Sciences, 2012, 1254, 140-150.	3.8	18
33	Cardiovascular defense challenges at the basic, clinical, and population levels. Annals of the New York Academy of Sciences, 2012, 1254, 1-6.	3.8	18
34	Role of the polypill for secondary prevention in ischaemic heart disease. European Journal of Preventive Cardiology, 2017, 24, 44-51.	1.8	17
35	Hemogram-derived ratios as prognostic markers of ICU admission in COVID-19. BMC Emergency Medicine, 2021, 21, 89.	1.9	15
36	Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study. Revista Espanola De Cardiologia (English Ed), 2017, 70, 42-49.	0.6	13

Jose Maria Castellano

#	Article	IF	CITATIONS
37	Are we ignoring the dilated thoracic aorta?. Annals of the New York Academy of Sciences, 2012, 1254, 164-174.	3.8	12
38	Promotion of Cardiovascular Health at Three Stages of Life: Never Too Soon, Never Too Late. Revista Espanola De Cardiologia (English Ed), 2014, 67, 731-737.	0.6	12
39	Optimal pharmacological treatment and adherence to medication in secondary prevention of cardiovascular events in Spain: Results from the <scp>CAPS</scp> study. Cardiovascular Therapeutics, 2017, 35, e12240.	2.5	12
40	Quantitative assessment of right ventricular function in pectus excavatum. Journal of Thoracic and Cardiovascular Surgery, 2012, 143, e41-e42.	0.8	11
41	Myocardial Amyloid Quantification with Look-Locker Magnetic Resonance Sequence in Cardiac Amyloidosis. Diagnostic Accuracy in Clinical Practice and Histological Validation. Journal of Cardiac Failure, 2018, 24, 78-86.	1.7	10
42	Polypill strategy at the heart of cardiovascular secondary prevention. Heart, 2019, 105, 9-10.	2.9	8
43	The influence of obesity on the assessment of carotid intimaâ€media thickness. Journal of Clinical Ultrasound, 2012, 40, 479-485.	0.8	7
44	Amyloid-β Increases Metallo- and Cysteine Protease Activities in Human Macrophages. Journal of Vascular Research, 2014, 51, 58-67.	1.4	6
45	Coronary Vasospasm Attributable to Fibromuscular Dysplasia. Circulation: Heart Failure, 2013, 6, e31-2.	3.9	4
46	Polypill, el policomprimido cardiovascular: del concepto a la realidad en España. Revista Espanola De Cardiologia Suplementos, 2015, 15, 19-24.	0.2	4
47	Barriers and Solutions to Improve Therapeutic Adherence from the Perspective of Primary Care and Hospital-Based Physicians. Patient Preference and Adherence, 2022, Volume 16, 697-707.	1.8	4
48	Polypill: Chimera or Reality?. Revista Espanola De Cardiologia (English Ed), 2014, 67, 689-692.	0.6	1
49	Risk factors and therapeutic coverage at 6â€years in patients with previous myocardial infarction: the CASTUO study. Open Heart, 2016, 3, e000368.	2.3	1
50	A very unusual cause of mechanical left ventricular outflow tract obstruction. European Journal of Cardio-thoracic Surgery, 2013, 44, 579-580.	1.4	0